SCI's research focus is in Advanced Lipid Technology (ALT) and their formulations:
Our primary research is in the area of Advanced Lipid Technology. With over twenty years of experience in this area, SCI is pursuing a multitude of challenges in medical and formulations research. Lipids such as Omega-3 are complex, long chained fatty acids. There are many such fatty acids having pharmacological activity. Of the myriad of substances, only two have been shown to be useful in the control of cardiovascular disease. Eicosapentaenoic (EPA) and docosahexaenoic acids (DHA) are the active ingredients in an approved US pharmaceutical product.
Recent clinical studies indicate that only one of these, EPA, may contribute to significant levels of activity. Our research has been channeled toward better understanding the chemistry and analytics of this potent fatty acid, developing advanced manufacturing techniques aimed at isolation and purification of EPA and the creation of formulations to improve its use to treat hypertriglyceridemia; a disease that may impact over 100 million people.
We also focus on the application of Soft Gelatin Encapsulation for the delivery of Lipid based drugs. In order to commercialize the work surrounding our essential fatty acids (such as EPA), we have developed significant expertise and technology to manufacture soft gelatin formulations. Since these fatty acids are oils, the delivery system and subsequent production technology is essential to the sustainable growth of the company.
There are only a handful of companies in the U.S. that can produce soft gelatin drug products and fewer yet that can develop products utilizing this delivery system.
Also visit: www.oceanblueprofessional.com